RxDoctor Payments Data

Jill Mitchell, DO

Internal Medicine · Lansing, MINPI 1457585002

Payments from drug & device makers

$5,774in general payments, 2019–2025

Across 283 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$871
  • AstraZeneca$709
  • Mallinckrodt Hospital Products Inc.$551
  • Vifor Pharma, Inc.$409
  • Otsuka America Pharmaceutical, Inc.$394
  • Calliditas Therapeutics US Inc.$333
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$5,46295%
  • Education$3115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,774 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$172,007
Medicare patients
230
Services billed
1,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$43,382
VelphoroSucroferric Oxyhydroxide12$37,788
JardianceEmpagliflozin34$36,777
LokelmaSodium Zirconium Cyclosilicate22$24,296
Sevelamer Carbonate18$3,601
Bumetanide88$3,304
Potassium Citrate ErPotassium Citrate25$2,852
Carvedilol160$2,343
Losartan Potassium166$1,751
Nifedipine ErNifedipine58$1,399
Lisinopril168$1,299
Amlodipine Besylate169$1,188
Hydralazine Hcl48$1,166
Doxazosin Mesylate49$1,040
Allopurinol91$978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$709$67,67860 claims
Fresenius USA Marketing, Inc.Velphoro$190$37,78812 claims
Boehringer IngelheimJardiance$141$36,77734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →